◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › R › RGNX

Regenxbio Inc (RGNX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-27

Regenxbio Inc (RGNX) operates in the BIOTECHNOLOGY industry and is headquartered in Rockville, United States with about 371 employees. Its market capitalization is roughly $504 million. In the fiscal year ended 2025-12-31, RGNX reported $170M in revenue and ($194M) in net income.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

Interactive charts & full statements → Open the RGNX valuation workbench →

RGNX Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Revenue	$174M	$170M	$83M	$90M	$113M	$470M	$155M	$35M	$219M	$10M	$5M	$8M	$6M	$6M
Gross Profit	$95M	$150M	$50M	$53M	$58M	$419M	$119M	$27M	$209M	$9M	$4M	$6M	$5M	$6M
Gross Margin %	54.2%	88.1%	59.7%	58.8%	51.6%	89.0%	76.9%	76.6%	95.6%	83.6%	79.1%	80.2%	83.5%	94.7%
Operating Income (EBIT)	($164M)	($161M)	($233M)	($268M)	($263M)	$160M	($119M)	($149M)	$88M	($76M)	($65M)	($23M)	($4M)	($5M)
Operating Margin %	-94.1%	-94.6%	-280.0%	-297.1%	-233.2%	34.0%	-77.1%	-422.9%	40.3%	-730.1%	-1423.8%	-304.9%	-60.2%	-78.5%
Net Income	($196M)	($194M)	($227M)	($263M)	($280M)	$128M	($111M)	($95M)	$100M	($73M)	($63M)	($23M)	($4M)	($5M)
Net Margin %	-112.6%	-113.8%	-272.5%	-292.0%	-248.7%	27.2%	-72.0%	-268.9%	45.7%	-704.0%	-1372.1%	-300.6%	-65.4%	-88.5%
EBITDA	($139M)	($133M)	($198M)	($239M)	($244M)	$177M	($97M)	($90M)	$92M	($73M)	($65M)	($23M)	($4M)	($5M)
Earnings Per Share (EPS)	$-3.79	$-3.76	$-4.59	$-6.02	$-6.50	$2.91	$-2.98	$-2.58	$2.73	$-2.45	$-2.38	$-2.49	$-0.30	$-2.04
Shares Outstanding (M)	53M	52M	50M	44M	43M	44M	37M	37M	37M	30M	26M	9M	13M	3M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RGNX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$108M	$6M	$30M	$30M	$21M	$89M	$21M	$24M
Gross Profit	$107M	($5M)	$24M	($32M)	$12M	$86M	$15M	$12M
Gross Margin %	99.0%	-73.2%	80.5%	-107.9%	57.3%	96.1%	70.2%	48.8%
Operating Income (EBIT)	$29M	($83M)	($58M)	($52M)	($63M)	$12M	($51M)	($62M)
Operating Margin %	27.1%	-1304.0%	-190.0%	-176.3%	-296.3%	13.6%	-242.1%	-256.6%
Net Income	$23M	($90M)	($67M)	($62M)	($71M)	$6M	($51M)	($60M)
Net Margin %	21.0%	-1408.6%	-221.3%	-208.3%	-331.8%	6.8%	-241.3%	-246.3%
EBITDA	$34M	($77M)	($51M)	($45M)	($56M)	$19M	($38M)	($55M)
Earnings Per Share (EPS)	$0.43	$-1.72	$-1.30	$-1.20	$-1.38	$0.12	$-1.01	$-1.17
Shares Outstanding (M)	53M	52M	52M	52M	51M	51M	51M	51M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RGNX Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Cash from Operations (CFO)	($247M)	($124M)	($173M)	($218M)	($207M)	$219M	($54M)	($108M)	$105M	($58M)	($49M)	($23M)	($2M)	($3M)
Capital Expenditures (CapEx)	$3M	$2M	$2M	$10M	$31M	$84M	$27M	$12M	$13M	$7M	$8M	$1M	$1M	$0M
Free Cash Flow (FCF)	($250M)	($126M)	($176M)	($228M)	($238M)	$135M	($81M)	($119M)	$91M	($65M)	($57M)	($23M)	($3M)	($3M)
FCF Margin %	-143.1%	-74.2%	-210.7%	-253.1%	-211.3%	28.6%	-52.4%	-339.0%	41.8%	-626.9%	-1235.7%	-303.6%	-47.7%	-49.5%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RGNX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($62M)	($76M)	($52M)	($56M)	($49M)	$34M	($32M)	($41M)
Capital Expenditures (CapEx)	$1M	$1M	$1M	$0M	$0M	$1M	$1M	$0M
Free Cash Flow (FCF)	($63M)	($77M)	($53M)	($56M)	($50M)	$33M	($33M)	($41M)
FCF Margin %	-58.3%	-1211.0%	-174.0%	-189.9%	-232.8%	36.6%	-154.2%	-168.9%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RGNX Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Assets	$387M	$453M	$466M	$574M	$833M	$1.1B	$708M	$498M	$544M	$199M	$173M	$221M	$3M	$3M
Cash & Cash Equivalents	$36M	$34M	$58M	$35M	$97M	$345M	$338M	$70M	$76M	$47M	$25M	$54M	$1M	$1M
Total Liabilities	$315M	$350M	$206M	$262M	$317M	$350M	$330M	$48M	$35M	$16M	$11M	$5M	$9M	$5M
Total Debt (Short + Long-Term)	$7M	$48M	$8M	$7M	$6M	$2M	$2M	$2M	$0M	$0M	$0M	$0M	$4M	$1M
Total Shareholders' Equity	$72M	$103M	$260M	$312M	$516M	$764M	$378M	$450M	$509M	$183M	$162M	$217M	($6M)	($2M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RGNX viewer.

Other Companies in BIOTECHNOLOGY

NGNE · Neurogene Inc — $534 million
ENTX · Entera Bio Ltd — $530 million
VALN · Valneva SE ADR — $522 million
FTH · Faeth Therapeutics, Inc. — $508 million
OVID · Ovid Therapeutics Inc — $496 million
CBIO · Crescent Biopharma, Inc. — $485 million
CAPR · Capricor Therapeutics Inc — $479 million
CTMX · CytomX Therapeutics Inc — $475 million

← RGLO All “R” companies RGP →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.